Kimberly-Clark beats profit estimates on cost cuts, essential products demand

The entrance sign to Kimberly-Clark Corporation world headquarters campus in Irving, Texas. (AP / L.M. Otero)

Kimberly-Clark exceeded quarterly profit expectations on Tuesday, helped by cost controls and steady demand for its products including Huggies diapers and Kleenex tissues.

Shares of the company, which had lost about 23 per cent of their value in 2025, were up about two per cent in trading before the bell.

The Dallas-based company has cut jobs and sold low-margin and non-essential businesses such as its private-label diaper and personal protective equipment segments in recent months.

• Latest updates on company news here

That has shielded margins as Kimberly-Clark expands its affordable ranges and offers lower-priced products that still carry premium features to attract cost-conscious customers and fight competition.

Prices declined 1.1 per cent while organic sales rose 2.1 per cent in the fourth quarter, driven by a 2.7 per cent growth in overall volumes as consumers stocked up on essential products such as surface cleaning agents, disinfectants and paper napkins at warehouse-style club stores that sell larger, value packs.

The company, which had previously warned that steep U.S. import duties, especially on Chinese goods, would hit profitability, posted an adjusted gross margin of 37 per cent, in line with the prior year.

Adjusted earnings per share of $1.86 were above analysts’ estimates of $1.81, according to data compiled by LSEG.

Net sales for the quarter ended December 30 totaled $4.08 billion, slightly shy of expectations of $4.09 billion.

Consumer goods bellwether Procter & Gamble also exceeded quarterly earnings expectations last week, despite revenue slightly being short of expectations.

Kimberly-Clark expects 2026 organic sales to be in line with or ahead of the roughly two per cent average growth seen across the categories and markets it competes in.

• Latest updates on international news here

It expects adjusted profit per share to grow at a double-digit rate, with margins expanding as it improves efficiencies.

The company has proposed buying Tylenol maker Kenvue for more than $40 billion to create a global consumer health company, with the deal expected to close by year-end.

(Reporting by Neil J Kanatt, Savyata Mishra in Bengaluru and Jessica DiNapoli in New York; Editing by Devika Syamnath)